Valuation: FunPep Company Limited

Market Cap 2.89B 17.86M 15.66M 14.43M 13.51M 25.34M 1.68B 25.86M 173M 67.12M 832M 67.05M 65.59M P/E 2024
-4.22x
P/E 2025 -1.63x
Enterprise Value 1.12B 6.92M 6.07M 5.59M 5.24M 9.82M 653M 10.02M 67.22M 26.01M 323M 25.99M 25.42M EV / Sales 2024
338x
EV / Sales 2025 -
Free-Float
79.81%
Yield 2024 *
-
Yield 2025 -
03-09 FunPep Company Limited announced that it has received ¥32.5315 million in funding from Next Growth Co., Ltd., Growth Capital, Inc. CI
02-20 FunPep Company Limited announced that it expects to receive ¥32.5315 million in funding from Next Growth Co., Ltd., Growth Capital, Inc. CI
10/03/25 FunPep Company Limited announced that it has received ¥3.6 million in funding from SBI Securities Co., Ltd. CI
21/02/25 FunPep Company Limited announced that it expects to receive ¥3.6 million in funding from SBI Securities Co., Ltd. CI
22/07/24 FunPep Company Limited announced that it has received ¥3.52 million in funding from SBI SECURITIES Co., Ltd. CI
05/07/24 FunPep Company Limited announced that it expects to receive ¥3.52 million in funding from SBI SECURITIES Co., Ltd. CI
21/03/24 FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
04/03/24 FunPep Company Limited announced that it expects to receive ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
14/11/23 FunPep Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
15/05/23 FunPep Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
01/10/22 FunPep Company Limited completed the acquisition of Anti-Aging Peptide Co., Ltd. from Hironori Nakagami , Bio Site Start Fund L.P., Naotaka Hashiya, Chiyako Ueda, ReBeage Co., Ltd. and others. CI
14/07/22 FunPep Company Limited agreed to acquire Anti-Aging Peptide Co., Ltd. from Hironori Nakagami , Bio Site Start Fund L.P., Naotaka Hashiya, Chiyako Ueda, ReBeage Co., Ltd. and others. CI
13/12/21 FunPep Company Limited announced that it has received ¥3.741 million in funding from SBI Securities Co., Ltd., Investment Arm CI
1 day+3.39%
1 week+1.67%
Current month+1.67%
1 month+1.67%
3 months-25.61%
6 months-22.78%
Current year-25.61%
1 week 59
Extreme 59
61
1 month 57
Extreme 57
80
Current year 57
Extreme 57
130
1 year 57
Extreme 57
130
3 years 57
Extreme 57
325
5 years 57
Extreme 57
492
10 years 57
Extreme 57
843
Manager TitleAgeSince
Director of Finance/CFO 53 01/05/2015
President 62 01/01/2020
Chief Tech/Sci/R&D Officer 54 01/07/2015
Director TitleAgeSince
Chairman 78 01/03/2015
Director/Board Member 62 01/03/2015
Director/Board Member 54 01/12/2015
Date Insider Type Main position Quantity % Market Cap.
28/04/25
Sola KK
OthersCompany 20,000 0.0617%
28/04/25
Sola KK
OthersCompany 50,000 0.1543%
28/04/25Others 40,000 0.1234%
Change 5-day change 1-year change 3-year change Capi.($)
+3.39%+1.67%-46.02%-68.06% 17.86M
+0.36%+7.19%-5.06%+2.56% 46.2B
+2.19%+11.71%+393.31%+580.42% 38.71B
+2.53%+13.93%+21.38%-12.81% 31.9B
+1.65%+3.61%+16.04%+55.62% 31.12B
-4.16%-2.58%+8.94%+25.31% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+130.07% 15.05B
-1.19%+7.34%+12.74%+20.60% 13.74B
+3.63%+9.53%+103.97%+98.73% 13.42B
Average +1.10%+8.06%+63.88%+92.49% 23.01B
Weighted average by Cap. +1.00%+8.71%+88.82%+131.23%

Financials

2024 2025
Net sales 6M 37.11K 32.54K 30K 28.08K 52.66K 3.5M 53.75K 361K 140K 1.73M 139K 136K -
Net income -889M -5.5M -4.82M -4.44M -4.16M -7.8M -519M -7.96M -53.42M -20.67M -256M -20.65M -20.2M -1.91B -11.82M -10.36M -9.55M -8.94M -16.77M -1.12B -17.12M -115M -44.43M -551M -44.39M -43.42M
Net Debt -2.35B -14.51M -12.72M -11.73M -10.98M -20.59M -1.37B -21.02M -141M -54.55M -677M -54.49M -53.3M -1.77B -10.94M -9.59M -8.84M -8.28M -15.52M -1.03B -15.84M -106M -41.11M -510M -41.07M -40.17M
Logo FunPep Company Limited
FunPep Co Ltd is a Japan-based company engaged in the research and development business for pharmaceuticals. The main business is to promote research and development of functional peptides, which are the results of research at the Graduate School of Medicine, Osaka University, and to put them into practical use in the business fields such as pharmaceuticals, cosmetics and medical devices. The business model defines its technical area as a functional peptide-based area and a related area that has synergies with it. The Research & Development pipeline is composed of research themes for antibody-inducing peptides and developed products. The Company is engaged in the sale of peptide active ingredients through cosmetic raw material trading companies or sales companies.
Employees
15
Date Price Change Volume
29/06/26 ¥61.00 +3.39% 77,500
26/06/26 ¥59.00 -3.28% 170,200
25/06/26 ¥61.00 +3.39% 156,500
24/06/26 ¥59.00 -1.67% 246,300
23/06/26 ¥60.00 0.00% 78,700

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4881 Stock